{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:24:19Z","timestamp":1760189059796},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,7,14]],"date-time":"2009-07-14T00:00:00Z","timestamp":1247529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s11936-009-0028-2","type":"journal-article","created":{"date-parts":[[2009,7,13]],"date-time":"2009-07-13T07:39:23Z","timestamp":1247470763000},"page":"272-278","source":"Crossref","is-referenced-by-count":30,"title":["Use of statins in patients with liver disease"],"prefix":"10.1007","volume":"11","author":[{"given":"Sweta","family":"Tandra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,14]]},"reference":[{"key":"28_CR1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","volume":"98","author":"J.M. Clark","year":"2003","unstructured":"Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960\u2013967.","journal-title":"Am J Gastroenterol"},{"key":"28_CR2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","volume":"7","author":"N. Rafiq","year":"2009","unstructured":"Rafiq N, Bai C, Fang Y, et al.: Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234\u2013238.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"28_CR3","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00125-008-1135-4","volume":"51","author":"G. Targher","year":"2008","unstructured":"Targher G, Marra F, Marchesini G: Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008, 51:1947\u20131953.","journal-title":"Diabetologia"},{"key":"28_CR4","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2007.01.021","volume":"46","author":"G. Targher","year":"2007","unstructured":"Targher G, Bertolini L, Padovani R, et al.: Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007, 46:1126\u20131132.","journal-title":"J Hepatol"},{"key":"28_CR5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archinternmed.2008.552","volume":"169","author":"V. Shalev","year":"2009","unstructured":"Shalev V, Chodick G, Silber H, et al.: Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009, 169:260\u2013268.","journal-title":"Arch Intern Med"},{"key":"28_CR6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/MOL.0b013e328319baba","volume":"19","author":"W.V. Brown","year":"2008","unstructured":"Brown WV: Safety of statins. Curr Opin Lipidol 2008, 19:558\u2013562.","journal-title":"Curr Opin Lipidol"},{"key":"28_CR7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","volume":"24","author":"S. Denus de","year":"2004","unstructured":"de Denus S, Spinler SA, Miller K, Peterson AM: Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24:584\u2013591.","journal-title":"Pharmacotherapy"},{"key":"28_CR8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection, Evaluation,Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486\u20132497.","journal-title":"JAMA"},{"key":"28_CR9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","volume":"89","author":"K.G. Tolman","year":"2002","unstructured":"Tolman KG: The liver and lovastatin. Am J Cardiol 2002, 89:1374\u20131380.","journal-title":"Am J Cardiol"},{"key":"28_CR10","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","volume":"135","author":"N. Chalasani","year":"2008","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, et al.: Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924\u20131934.","journal-title":"Gastroenterology"},{"key":"28_CR11","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"J.D. Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387\u20131395.","journal-title":"Hepatology"},{"key":"28_CR12","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N. Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287\u20131292.","journal-title":"Gastroenterology"},{"key":"28_CR13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","volume":"329","author":"R. Vuppalanchi","year":"2005","unstructured":"Vuppalanchi R, Teal E, Chalasani N: Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62\u201365.","journal-title":"Am J Med Sci"},{"key":"28_CR14","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","volume":"105","author":"M.A. Pfeffer","year":"2002","unstructured":"Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002, 105:2341\u20132346.","journal-title":"Circulation"},{"key":"28_CR15","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","volume":"57","author":"H. Hyogo","year":"2008","unstructured":"Hyogo H, Tazuma S, Arihiro K, et al.: Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711\u20131718.","journal-title":"Metabolism"},{"key":"28_CR16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/00365520500320060","volume":"41","author":"M.H. Ahmed","year":"2006","unstructured":"Ahmed MH: Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scand J Gastroenterol 2006, 41:631.","journal-title":"Scand J Gastroenterol"},{"key":"28_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","volume":"174","author":"L.S. Rallidis","year":"2004","unstructured":"Rallidis LS, Drakoulis CK, Parasi AS: Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004, 174:193\u2013196.","journal-title":"Atherosclerosis"},{"key":"28_CR18","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.22269","volume":"47","author":"M.Y. Sheikh","year":"2008","unstructured":"Sheikh MY, Choi J, Qadri I, et al.: Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008, 47:2127\u20132133.","journal-title":"Hepatology"},{"key":"28_CR19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cgh.2008.02.034","volume":"6","author":"I.A. Hanouneh","year":"2008","unstructured":"Hanouneh IA, Feldstein AE, Lopez R, et al.: Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008, 6:584\u2013589.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"28_CR20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","volume":"4","author":"S. Khorashadi","year":"2006","unstructured":"Khorashadi S, Hasson NK, Cheung RC: Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4:902\u2013907.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"28_CR21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjcard.2005.06.071","volume":"96","author":"K. Gibson","year":"2005","unstructured":"Gibson K, Rindone JP: Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol 2005, 96:1278\u20131279.","journal-title":"Am J Cardiol"},{"key":"28_CR22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1592\/phco.27.6.845","volume":"27","author":"M. Segarra-Newnham","year":"2007","unstructured":"Segarra-Newnham M, Parra D, Martin-Cooper EM: Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy 2007, 27:845\u2013851.","journal-title":"Pharmacotherapy"},{"key":"28_CR23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","volume":"194","author":"A. Sorokin","year":"2007","unstructured":"Sorokin A, Brown JL, Thompson PD: Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007, 194:293\u2013299.","journal-title":"Atherosclerosis"},{"key":"28_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M. Longo","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, et al.: Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002, 51:265\u2013269.","journal-title":"Gut"},{"key":"28_CR25","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1572-0241.2008.02092.x","volume":"103","author":"M. Solaymani-Dodaran","year":"2008","unstructured":"Solaymani-Dodaran M, Aithal GP, Card T, West J: Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008, 103:2784\u20132788.","journal-title":"Am J Gastroenterol"},{"key":"28_CR26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","volume":"55","author":"M. Allocca","year":"2006","unstructured":"Allocca M, Crosignani A, Gritti A, et al.: Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006, 55:1795\u20131800.","journal-title":"Gut"},{"key":"28_CR27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","volume":"46","author":"T. Stojakovic","year":"2007","unstructured":"Stojakovic T, Putz-Bankuti C, Fauler G, et al.: Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007, 46:776\u2013784.","journal-title":"Hepatology"},{"key":"28_CR28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","volume":"36","author":"U. Ritzel","year":"2002","unstructured":"Ritzel U, Leonhardt U, Nather M, et al.: Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002, 36:454\u2013458.","journal-title":"J Hepatol"},{"key":"28_CR29","first-page":"A732","volume":"132","author":"M.A. Abu Rajah","year":"2007","unstructured":"Abu Rajah MA, Kaplan MM: Statin use in patients with primary biliary cirrhosis (PBC): are they safe [abstract]? Gastroenterology 2007, 132:A732.","journal-title":"Gastroenterology"},{"key":"28_CR30","unstructured":"Lipitor [package insert]. New York, NY: Pfizer, Inc.; 2004."},{"key":"28_CR31","unstructured":"Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2003."},{"key":"28_CR32","unstructured":"Mevacor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002."},{"key":"28_CR33","unstructured":"Zocor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2004."},{"key":"28_CR34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"J.H. Lewis","year":"2007","unstructured":"Lewis JH, Mortensen ME, Zweig S, et al.: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453\u20131463.","journal-title":"Hepatology"},{"key":"28_CR35","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","volume":"97","author":"D.E. Cohen","year":"2006","unstructured":"Cohen DE, Anania FA, Chalasani N: An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:77C\u201381C.","journal-title":"Am J Cardiol"},{"key":"28_CR36","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"J. Abraldes","year":"2009","unstructured":"Abraldes J, Albillos A, Ba\u00f1ares R, et al.: Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651\u20131658.","journal-title":"Gastroenterology"},{"key":"28_CR37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","volume":"84","author":"S. Kawata","year":"2001","unstructured":"Kawata S, Yamasaki E, Nagase T, et al.: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84:886\u2013891.","journal-title":"Br J Cancer"},{"key":"28_CR38","first-page":"1099","volume":"51","author":"C. Lersch","year":"2004","unstructured":"Lersch C, Schmelz R, Erdmann J, et al.: Treatment of HCC with pravastatin, octreotide, or gemcitabine\u2014a critical evaluation. Hepatogastroenterology 2004, 51:1099\u20131103.","journal-title":"Hepatogastroenterology"},{"issue":"Suppl1","key":"28_CR39","first-page":"29","volume":"1","author":"S.J. Mu\u00f1oz","year":"1995","unstructured":"Mu\u00f1oz SJ: Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1995, 1(Suppl 1):29\u201338.","journal-title":"Liver Transpl Surg"},{"key":"28_CR40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1432-2277.2002.tb00107.x","volume":"15","author":"C. Fernandez-Miranda","year":"2002","unstructured":"Fernandez-Miranda C, Sanz M, dela Calle A, et al.: Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002, 15:556\u2013562.","journal-title":"Transpl Int"},{"key":"28_CR41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-0012.2007.00780.x","volume":"22","author":"J.E. Martin","year":"2008","unstructured":"Martin JE, Cavanaugh TM, Trumbull L, et al.: Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant 2008, 22:113\u2013119.","journal-title":"Clin Transplant"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-009-0028-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-009-0028-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-009-0028-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:34Z","timestamp":1559436994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-009-0028-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,14]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s11936-009-0028-2","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,14]]}}}